期刊
PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
卷 31, 期 3, 页码 119-131出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/ped.2018.0901
关键词
asthma; asthma medications; asthma biomarkers; biologic therapies
资金
- Novartis
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- GlaxoSmithKline
- Colorado Department of Public Health and Environment Colorado Cancer, Cardiovascular, and Pulmonary Disease Program
There is increasing recognition of phenotypic variability in pediatric asthma, providing the opportunity for a more personalized approach to therapy. Increasingly biologic therapies, in particular those targeting the allergic (or T helper 2) pathway, are being considered for children with severe asthma. However, there is a great deal of variability in the extent these biologic therapies have been studied in children, as well as efficacy of results thus far. The goal of this article is to review the mechanism of action, efficacy, and potential predictive and monitoring biomarkers of the biologic medications focusing on the pediatric population, in an effort to establish a more personalized approach to asthma in the pediatric population for the 21st century.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据